OrthoPediatrics Corp. (KIDS), a Warsaw, Indiana-based medical device maker focused exclusively on pediatric orthopedics, is covered by eight analysts with a consensus rating of Buy. Their individual 12-month price targets range from a low of $27 (Stifel) to a high of $38 (Lake Street), with an overall mean of approximately $30.75. Because that mean sits essentially at or below the latest share price, it fails to provide a meaningful upside target.
Applying a minimum-distance standard, only two of the eight targets remain above the current price: $35 and $38. Their average is $36.50, rounded to $37, which serves as the central target for this analysis. This is the average of analyst targets above the current price, not an official consensus; the full average of all eight targets ($30.75) and the complete range ($27–$38) are provided for context.
Views differ sharply. Hold-rated Truist argues the stock trades at a valuation premium versus peers that already reflects its growth and emerging profitability. More bullish firms such as TD Cowen, Canaccord, Piper Sandler, BTIG, and Lake Street point to strong top-line momentum, new product contributions, and a multi-year growth runway. Recent actions have been broadly positive, with several firms raising targets after third-quarter results.
Shares of KIDS recently closed near $30.87, just below a 52-week high around $32.62, after a powerful multi-month rally. Reaching the $37 central target would require a rise of roughly 20%, a substantial move from current levels.
The path is supported by fundamental momentum: third-quarter 2026 revenue of $72.7 million rose 19% year over year, and management raised full-year revenue guidance to $270–$273 million, implying 14–16% growth. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached a record $6.9 million, and free cash flow turned positive. Still, the company remains unprofitable on a GAAP basis, posting a net loss of $5.9 million, or $0.25 per share, in the quarter.
Several factors could support a continued advance. OrthoPediatrics is in what management calls an innovation "Super Cycle," with new products such as the 3P Hip plating system, Traxio, and VerteGlide beginning to contribute revenue. Its specialty bracing franchise (OPSB) grew more than 20%, with over 60 clinics and 34 product systems. International revenue rose 18%, aided by new European launches following regulatory approvals.
Critically, the company is improving its financial profile: 74% gross margins, record adjusted EBITDA, positive free cash flow, and guidance for breakeven free cash flow in 2026 and positive free cash flow in 2027. Analyst revisions have been mostly upward, and consensus sentiment remains Buy.
The principal obstacle is valuation. The stock's sharp run — roughly a 91% one-year gain — has outpaced analyst targets, leaving the broader sell-side mean below the current price. Persistent GAAP net losses and an EPS (earnings per share) that remains negative mean the stock is still priced on growth expectations rather than current profitability.
Other risks include margin pressure from the lower-margin bracing business, elevated sales and marketing spending (up 24% year over year), foreign-exchange and Latin America set-sales headwinds, and the inherent uncertainty of commercializing many new products simultaneously. If execution slips or multiple expansion stalls, the stock could consolidate well short of $37.
From a technical standpoint, KIDS trades just under its 52-week high near $32.62, which now acts as the immediate resistance level. A decisive move through that area would clear a meaningful overhead milestone on the way toward the $37 target. On the downside, the pre-earnings consolidation zone near $24–$25 represents a potential support level, with the psychological $30 mark serving as nearer-term support. The long-term trend is decisively upward after recovering from a 52-week low near $14.42.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary in their methodology and timeline. Investors should watch upcoming quarterly results, further full-year guidance updates, new product launch progress (including the transition from limited to full commercial release), adjusted EBITDA and free cash flow trajectory, and any additional analyst target revisions. Macroeconomic factors such as hospital procedure volumes, interest rates, and currency moves may also influence the path.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. For a stock like OrthoPediatrics, where momentum and valuation are both in focus, such tools can help traders spot changing trends, monitor positions, and discover opportunities more efficiently than manual screening alone. Traders seeking a systematic edge can explore these signals as part of a broader research process.
The question of whether OrthoPediatrics (KIDS) can reach $37 hinges on whether its fundamental momentum can extend a rally that has already outpaced most analyst expectations. The $37 figure represents the average of the two analyst targets above the current price, against an overall mean of $30.75 and a range of $27 to $38. That wide dispersion underscores genuine disagreement: bulls see a multi-year product cycle driving sustained growth, while skeptics argue the valuation already reflects the optimism. Reaching $37 would require roughly a 20% advance from recent levels — substantial but not unprecedented for a stock posting 19% revenue growth and improving cash flow. Investors should monitor execution on new product launches, progress toward profitability, and whether analyst targets catch up to the share price.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, KIDS has been loosely correlated with CNMD. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KIDS jumps, then CNMD could also see price increases.
| Ticker / NAME | Correlation To KIDS | 1D Price Change % | ||
|---|---|---|---|---|
| KIDS | 100% | -1.50% | ||
| CNMD - KIDS | 50% Loosely correlated | -1.41% | ||
| XRAY - KIDS | 48% Loosely correlated | +1.68% | ||
| OFIX - KIDS | 45% Loosely correlated | -9.87% | ||
| GEHC - KIDS | 44% Loosely correlated | -0.45% | ||
| MDT - KIDS | 42% Loosely correlated | -1.17% | ||
More | ||||
| Ticker / NAME | Correlation To KIDS | 1D Price Change % |
|---|---|---|
| KIDS | 100% | -1.50% |
| Medical/Nursing Services industry (138 stocks) | -1% Poorly correlated | -1.46% |
| Health Services industry (239 stocks) | -1% Poorly correlated | -1.13% |